Clinical trial

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT03924856

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gemcitabine Normalized identity: gemcitabine View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-06-13

PhasePHASE3

Conditions

Bladder Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

GemcitabineDRUG · verified · RxNorm: gemcitabine

CisplatinDRUG · verified · RxNorm: cisplatin

Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])PROCEDURE

PlaceboDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

SeoulSouth Korea4 IstanbulTurkey (Türkiye)3 TorontoOntario, Canada2 MadridSpain2 BerlinGermany2 JerusalemIsrael2 LondonLondon, City of, United Kingdom2 Saint PetersburgSankt-Peterburg, Russia2 BangkokBangkok, Thailand2 MoscowMoscow, Russia2 New YorkNew York, United States1 HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03924856 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.